Stock search

Ticker or company name

Amgen

AMGN · NASDAQ · Biotechnology

$462,32Down −3,35 (−0,72%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$252 bn
Div. yield
3,2%
Year to date
+42,7%
52 weeks: $312,39$483,99

Ratio score

67/100
Ratio would watch

based on 9 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

4 ✓ · 4 — · 1 ✕ · 1 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM26,822,642,1
Forward P/E19,2—18,7
PEG5,9—4,1
P/S6,54,96,6
EV/EBITDA18,214,328,2
P/FCF24,8—26,0
P/B17,623,49,8

Industry median — across 6 profitable companies in “Biotechnology” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 42 analysts

Buy
18
Hold
20
Sell
4

Beat the EPS forecast in 4 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20265,916,45Up +9,2%
Q2 20265,736,29Up +9,8%
Q1 20264,855,15Up +6,1%
Q4 20254,835,29Up +9,6%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue10,4 bn10,1 bn8,62 bn9,87 bn9,56 bn9,18 bn8,15 bn9,09 bn8,50 bn8,39 bn7,45 bn8,20 bn
EPS7,084,373,342,465,932,653,201,165,221,38−0,211,43
Margin37,3%23,6%21,1%13,5%33,7%15,6%21,2%6,9%33,3%8,9%−1,5%9,4%
FCF3,65 bn3,49 bn1,48 bn961 m4,25 bn1,91 bn980 m4,40 bn3,31 bn2,22 bn459 m289 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $26,7 m.

NameAmountSharesPrice
khosla rachna13 Aug 2026 · sale$521 3651 252$416,43
khosla rachna11 Aug 2026 · sale$825 1342 000$412,57
miller derek6 Aug 2026 · sale$733 0331 821$402,54
miller derek6 Aug 2026 · sale$832 8642 069$402,54
grygiel nancy a.6 Aug 2026 · sale$402 1601 000$402,16
grygiel nancy a.6 Aug 2026 · sale$792 2551 970$402,16
grygiel nancy a.4 May 2026 · sale$400 4511 237$323,73
santos esteban26 Feb 2026 · sale$9,21 m24 291$379,12
santos esteban26 Feb 2026 · sale$11,6 m30 501$379,12
busch matthew c.19 Feb 2026 · sale$375 7901 000$375,79
grygiel nancy a.20 Nov 2025 · sale$552 7731 639$337,26
grygiel nancy a.20 Nov 2025 · sale$505 8941 500$337,26

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Biotechnology
Exchange
NASDAQ
Country
US
IPO date
17 Jun 1983

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
GILDGilead Sciences$167,5825would not consider—+6,5%−12,5%
VRTXVertex Pharmaceuticals$537,7972would consider33,7+10,5%30,7%
ABBVAbbVie$294,5572would consider50,4+10,7%15,7%
REGNRegeneron Pharmaceuticals$952,4067would watch20,5+18,6%28,5%
MRNAModerna$215,2722would not consider—+13,1%−110,5%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.